648 related articles for article (PubMed ID: 30149876)
41. Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.
Damhofer H; Ebbing EA; Steins A; Welling L; Tol JA; Krishnadath KK; van Leusden T; van de Vijver MJ; Besselink MG; Busch OR; van Berge Henegouwen MI; van Delden O; Meijer SL; Dijk F; Medema JP; van Laarhoven HW; Bijlsma MF
J Transl Med; 2015 Apr; 13():115. PubMed ID: 25884700
[TBL] [Abstract][Full Text] [Related]
42. Transgenic Mouse Models in Cancer Research.
Lampreht Tratar U; Horvat S; Cemazar M
Front Oncol; 2018; 8():268. PubMed ID: 30079312
[TBL] [Abstract][Full Text] [Related]
43. Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity.
Liu L; Chen Q; Ruan C; Chen X; Zhang Y; He X; Zhang Y; Lu Y; Guo Q; Sun T; Wang H; Jiang C
Theranostics; 2018; 8(11):2974-2987. PubMed ID: 29896297
[TBL] [Abstract][Full Text] [Related]
44. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note.
Paez-Ribes M; Man S; Xu P; Kerbel RS
PLoS One; 2016; 11(6):e0158034. PubMed ID: 27355476
[TBL] [Abstract][Full Text] [Related]
45. Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.
Morton JJ; Bird G; Refaeli Y; Jimeno A
Cancer Res; 2016 Nov; 76(21):6153-6158. PubMed ID: 27587540
[TBL] [Abstract][Full Text] [Related]
46. Humanized mouse models for anti-cancer therapy.
Baietti MF; Leucci E
Methods Cell Biol; 2024; 183():317-333. PubMed ID: 38548416
[TBL] [Abstract][Full Text] [Related]
47. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
48. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
49. Natural killer cells and cytotoxic T lymphocytes are required to clear solid tumor in a patient-derived xenograft.
Le DT; Huynh TR; Burt B; Van Buren G; Abeynaike SA; Zalfa C; Nikzad R; Kheradmand F; Tyner JJ; Paust S
JCI Insight; 2021 Jul; 6(13):. PubMed ID: 34081628
[TBL] [Abstract][Full Text] [Related]
50. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
51. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
Liu M; Wang H; Liu L; Wang B; Sun G
J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
[TBL] [Abstract][Full Text] [Related]
52. Breast Cancer Xenograft Murine Models.
Fernando W; Coyle KM; Marcato P
Methods Mol Biol; 2022; 2508():31-44. PubMed ID: 35737231
[TBL] [Abstract][Full Text] [Related]
53. The host immunological response to cancer therapy: An emerging concept in tumor biology.
Voloshin T; Voest EE; Shaked Y
Exp Cell Res; 2013 Jul; 319(11):1687-95. PubMed ID: 23518388
[TBL] [Abstract][Full Text] [Related]
54. Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy.
Mett V; Komarova EA; Greene K; Bespalov I; Brackett C; Gillard B; Gleiberman AS; Toshkov IA; Aygün-Sunar S; Johnson C; Karasik E; Bapardekar-Nair M; Kurnasov OV; Osterman AL; Stanhope-Baker PS; Morrison C; Moser MT; Foster BA; Gudkov AV
Oncogene; 2018 Jan; 37(4):439-449. PubMed ID: 28967901
[TBL] [Abstract][Full Text] [Related]
55. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
56. Patient-derived xenograft models for personalized medicine in colorectal cancer.
Xie J; Lin Y
Clin Exp Med; 2020 May; 20(2):167-172. PubMed ID: 32100151
[TBL] [Abstract][Full Text] [Related]
57. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours.
Braekeveldt N; Wigerup C; Tadeo I; Beckman S; Sandén C; Jönsson J; Erjefält JS; Berbegall AP; Börjesson A; Backman T; Øra I; Navarro S; Noguera R; Gisselsson D; Påhlman S; Bexell D
Cancer Lett; 2016 Jun; 375(2):384-389. PubMed ID: 27000989
[TBL] [Abstract][Full Text] [Related]
58. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
59. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
60. Advances in Human Immune System Mouse Models for Personalized Treg-Based Immunotherapies.
Serr I; Kral M; Scherm MG; Daniel C
Front Immunol; 2021; 12():643544. PubMed ID: 33679808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
